Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond

References

• Tomita M, Sendju Y. Uber die Oxyaminverbindungen welche die Biuret Reaktionen zeigen. III. Spaltung der gamma-amino-beta-oxybuttersaure in die optisch-aktiven Komponente. Z Physiol. Chem. 169, 263–277 (1927).
   Google Scholar
• Gulewitsch W, Krimberg R. Zur Kenntnis der Extractivstoffe der Muskeln. Z Physiol. Chem. 45, 326–328 (1905).
   Google Scholar
• Kutscher F. Zur Kenntnis des Novains. Z Physiol. Chem. 49, 47–49 (1905).
   Google Scholar
• Fraenkel G, Blewett M, Coles M. BT, a new vitamin of the group and its relation to the folic acid group, and other anti-anaemia factors. Nature 161, 981–983 (1948).
   PubMed Web of Science ®Google Scholar
• Fritz IB. The effects of muscle extracts on the oxidation of palmitic acid by liver slices and homogenates. Acta. Physiol. Scand. 34, 367–385 (1955).
   PubMedGoogle Scholar
• Bremer J. Carnitine in intermediary metabolism. The metabolism of fatty acid esters of carnitine by mitochondria. J. Biol. Chem. 237, 2228–2231 (1962).
   PubMedGoogle Scholar
• Engel AG, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science 179, 899–902 (1973).
   PubMed Web of Science ®Google Scholar
• Angelini C, Vergani L. Primary Myopathic and Systemic Carnitine Deficiency Syndromes: New Concepts from Transport Studies. Ponte Press, Verlags-GmbH, Bochum (1996).
   Google Scholar
• Scholte HR, de Jonge PC. In: Metabolism, Function and Transport of Carnitine in Health and Disease. Gitzelmann R et al. (Eds.). Schattauer-Verlag, Stuttgart (1987).
   Google Scholar
• Friedman S, Fraenkel G. Reversible enzymatic acetylation of carnitine. Arch. Biochem. Biophys. 59(2), 491–501 (1955).
   PubMed Web of Science ®Google Scholar
• Pande SV. A mitochondrial carnitine acylcarnitine translocase system. Proc. Natl. Acad. Sci. U.S.A. 72(3), 883–887 (1975).
   PubMedGoogle Scholar
• Weger P. Zur physiologie des carnitins und des acetylcarnitins. Biochim. Z. 287, 424–432 (1936).
   Google Scholar
• Strack E, Fosterling K. Uber die biologische Wirkung des carnitins und azetylcarnitins. Arch. Exper. Pathol. Pharmakol. 185, 612–662 (1937).
   Google Scholar
• Dolez al V, Tuc ek S. Utilization of citrate, acetylcarnitine, acetate, pyruvate and glucose for the synthesis of acetylcholine in rat brain slices. J. Neurochem. 36, 1323–1330 (1981).
   PubMedGoogle Scholar
• White HL, Scates PW. Acetyl-L-carnitine as a precursor of acetylcholine. Neurochem. Res. 15(6), 597–601 (1990).
   PubMedGoogle Scholar
• Herzmann C, Whiting SJ, Thomas M, Byrne P, Johnson MA, Youle M. Pharmacokinetics of Acetyl-L-carnitine given in single or multiple doses to HIV-1 infected patients with toxic peripheral polyneuropathy. Open AIDS J. 2, 39–42 (2008).
   PubMedGoogle Scholar
• Goa KL, Brogden A. l-Carnitine, a preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs 34, 1–24 (1987).
   PubMed Web of Science ®Google Scholar
• Furlong JH. Acetyl-L-carnitine: Metabolism and applications in clinical practice. Altern. Med. Rev. 1(22), 85–92 (1996).
   Google Scholar
• Calvani M, Carta A. Clues to the mechanism of action of Acetyl-L-carnitine in the central nervous system. Dementia 2, 1–6 (1991).
   Google Scholar
• Piovesan P, Quatrini G, Pacifici L, Taglialatela G, Angelucci L. Acetyl-L-carnitine restores choline acetyltransferase activity in the hippocampus of rats with partial unilateral fimbria-fornix transection. Int. J. Devl. Neurosci. 13, 13–19 (1995).
   PubMedGoogle Scholar
• Daily JW, Sachan DS. Choline supplementation alters carnitine homeostasis in humans and guinea pigs. J. Nutr. 125, 1938–1944 (1995).
   PubMed Web of Science ®Google Scholar
• Chiechio S, Copani A, De Petris L, Morales ME, Nicoletti F, Gereau RW 4th. Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-kappaB pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of l-acetylcarnitine. Mol. Pain 2, 20 (2006).
   PubMedGoogle Scholar
• Malone JI, Lowitt S, Corsico N, Orfalian Z. Altered neuroexcitability in experimental diabetic neuropathy: effect of Acetyl-L-carnitine. Int. J. Clin. Pharmacol. Res. 12(5–6), 237–241 (1992).
   PubMedGoogle Scholar
• Onofrj M, Fulgente T, Melchionda D et al. l-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain. Int. J. Clin. Pharmacol. Res. 15(1), 9–15 (1995).
   PubMedGoogle Scholar
• Fernandez E, Pallini R, Lauretti L et al. Levocarnitine acetyl prevents cell death following long-term section of the vagus nerve in rats. Int. J. Clin. Pharmacol. Res. 12(5–6), 289–297 (1992).
   PubMedGoogle Scholar
• Gorio A, Di Giulio AM, Tenconi B et al. Peptide alterations in autonomic diabetic neuropathy prevented by Acetyl-L-carnitine. Int. J. Clin. Pharmacol. Res. 12(5–6), 225–230 (1992).
   PubMedGoogle Scholar
• Quatraro A, Roca P, Donzella C, Acampora R, Marfella R, Giugliano D. Acetyl-L-carnitine for symptomatic diabetic neuropathy. Diabetologica 38, 123 (1995).
   PubMedGoogle Scholar
• Lowitt S, Malone JI, Salem AF, Korthals J, Benford S. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 44, 677–680 (1995).
   PubMed Web of Science ®Google Scholar
• Sima AA. Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data. CNS Drugs 21(1), 13–23; (2007).
   PubMedGoogle Scholar
• Chiechio S, Copani A, Nicoletti F, Gereau RW 4th. l-acetylcarnitine: a proposed therapeutic agent for painful peripheral neuropathies. Curr. Neuropharmacol. 4(3), 233–237 (2006).
   PubMed Web of Science ®Google Scholar
• Young MJ, Boulton AJM, Macleod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinical population. Diabetalogica 36, 150–154 (1993).
   PubMed Web of Science ®Google Scholar
• Merry AC, Kamijo M, Lattimer S et al. Long-term prevention and intervention effects of Acetyl-L-carnitine on diabetic neuropathy in BB/W-rats. Diabetes 43, 108A (1994).
   Google Scholar
• Chiechio S, Caricasole A, Barletta E et al. l-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. Mol. Pharmacol. 61(5), 989–996 (2002).
   PubMed Web of Science ®Google Scholar
• Chiechio S, Copani A, Gereau RW 4th, Nicoletti F. Acetyl-L-carnitine in neuropathic pain: experimental data. CNS Drugs 21(1), 31–38 (2007).
   PubMedGoogle Scholar
• Chiechio S, Copani A, Zammataro M, Battaglia G, Gereau RW 4th, Nicoletti F. Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends Pharmacol. Sci. 31(4), 153–160 (2010).
   PubMedGoogle Scholar
• Chiechio S, Copani A, Melchiorri D et al. Metabotropic receptors as targets for drugs of potential use in the treatment of neuropathic pain. J. Endocrinol. Invest. 27(6), 171–176 (2004).
   PubMedGoogle Scholar
• Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205–237 (1997).
   PubMed Web of Science ®Google Scholar
• Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38(10), 1431–1476 (1999).
   PubMed Web of Science ®Google Scholar
• Vardi N, Duvoisin R, Wu G, Sterling P. Localization of mGluR6 to dendrites of ON bipolar cells in primate retina. J. Comp. Neurol. 423(3), 402–412 (2000).
   PubMed Web of Science ®Google Scholar
• Varney MA, Gereau RW 4th. Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr. Drug. Targets CNS 1(3), 283–296 (2002).
   PubMedGoogle Scholar
• Saab CY, Wang J, Gu C, Garner KN, Al-Chaer ED. Microglia: a newly discovered role in visceral hypersensitivity? Neuron Glia Biol. 2(4), 271–277 (2006).
   PubMedGoogle Scholar
• D’Antoni S, Berretta A, Bonaccorso CM et al. Metabotropic glutamate receptors in glial cells. Neurochem. Res. 33(12), 2436–2443 (2008).
   PubMed Web of Science ®Google Scholar
• Chiechio S, Nicoletti F. Metabotropic glutamate receptors and the control of chronic pain. Curr. Opin. Pharmacol. 12(1), 28–34 (2012).
   PubMed Web of Science ®Google Scholar
• Zammataro M, Chiechio S, Montana MC et al. mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists. Mol. Pain 14, 7 (2011).
   Google Scholar
• Gerber G, Zhong J, Youn D, Randic M. Group II and group III metabotropic glutamate receptor agonists depress synaptic transmission in the rat spinal cord dorsal horn. Neuroscience 100(2), 393–406 (2000).
   PubMed Web of Science ®Google Scholar
• Carlton SM, Du J, Zhou S. Group II metabotropic glutamate receptor activation on peripheral nociceptors modulates TRPV1 function. Brain Res. 1248, 86–95 (2009).
   PubMedGoogle Scholar
• Jones CK, Eberle EL, Peters SC, Monn JA, Shannon HE. Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing. Neuropharmacology 49(1), 206–218 (2005).
   PubMedGoogle Scholar
• Chiechio S, Zammataro M, Morales ME et al. Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain. Mol. Pharmacol. 75(5), 1014–1020 (2009).
   PubMed Web of Science ®Google Scholar
• Bird AP, Wolffe AP. Methylation-induced repression–belts, braces, and chromatin. Cell 99(5), 451–454 (1999).
   PubMed Web of Science ®Google Scholar
• Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 15(286), 481–486 (1999).
   Google Scholar
• Davie JR, Spencer VA. Control of histone modifications. J. Cell. Biochem. 32(33), 141–148 (1999).
   PubMedGoogle Scholar
• Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31(2), 89–97 (2006).
   PubMed Web of Science ®Google Scholar
• Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26(37), 5310–5318 (2007).
   PubMed Web of Science ®Google Scholar
• Kurita M, Holloway T, García-Bea A et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat. Neurosci. 15(9), 1245–1254 (2012).
   PubMed Web of Science ®Google Scholar
• Sima AA, Calvani M, Mehra M, Amato A; Acetyl-L-carnitine Study Group. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 28(1), 89–94 (2005).
   PubMed Web of Science ®Google Scholar
• De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs 21(1), 39–43 (2007).
   PubMed Web of Science ®Google Scholar
• Scarpini E, Sacilotto G, Baron P, Cusini M, Scarlato G. Effect of Acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J. Peripher. Nerv. Syst. 2(3), 250–252 (1997).
   PubMedGoogle Scholar
• Hart AM, Wilson AD, Mantovani C et al. Acetyl-L-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 18(11), 1549–1560 (2004).
   PubMed Web of Science ®Google Scholar
• Gambi D, Onofrj M, Calvani M et al. Neurophysiological studies of l-acetylcarnitine administration in man. Drugs Exp. Clin. Res. 15(9), 435–446 (1989).
   PubMedGoogle Scholar
• Bodis-Wollner I. Physiological effects of Acetyl-Levo-carnitine in the central nervous system. Int. J. Clin. Pharmacol. Res. 10(1–2), 109–114 (1990).
   PubMedGoogle Scholar
• Rai G, Wright G, Scott L, Beston B, Rest J, Exton-Smith AN. Double-blind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer’s dementia. Curr. Med. Res. Opin. 11(10), 638–647 (1990).
   PubMed Web of Science ®Google Scholar
• Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst. Rev. 2, 3158 (2003).
   Google Scholar
• Passeri M, Cucinotta D, Bonati PA, Iannuccelli M, Parnetti L, Senin U. Acetyl-L-carnitine in the treatment of mildly demented elderly patients. Int. J. Clin. Pharmacol. Res. 10(1–2), 75–79 (1990).
   PubMedGoogle Scholar
• Sinforiani E, Iannuccelli M, Mauri M et al. Neuropsychological changes in demented patients treated with Acetyl-L-carnitine. Int. J. Clin. Pharmacol. Res. 10(1–2), 69–74 (1990).
   PubMedGoogle Scholar
• Spagnoli A, Lucca U, Menasce G et al. Long-term Acetyl-L-carnitine treatment in Alzheimer’s disease. Neurology 41(11), 1726–1732 (1991).
   PubMed Web of Science ®Google Scholar
• Onofrj M, Thomas A, Iacono D, Luciano AL, Di Iorio A. The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia. Clin. Neuropharmacol. 26(5), 239–251 (2003).
   PubMed Web of Science ®Google Scholar
• Thal LJ, Carta A, Clarke WR et al. A one-year multicenter placebo-controlled study of Acetyl-L-carnitine in patients with Alzheimer’s disease. Neurology 47(3), 705–711 (1996).
   PubMed Web of Science ®Google Scholar
• Brooks JO 3rd, Yesavage JA, Carta A, Bravi D. Acetyl l-carnitine slows decline in younger patients with Alzheimer’s disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int Psychogeriatr 10(2), 193–203 (1998).
   PubMedGoogle Scholar
• Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of Acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. Int. Clin. Psychopharmacol. 18(2), 61–71 (2003).
   PubMed Web of Science ®Google Scholar
• Onofrj M, Bodis-Wollner I, Calvani M. Effect of L-acetyl carnitine HCl on rat steady-state visual evoked potentials. Comparison with l-carnitine. Drugs Exp. Clin. Res. 13(1), 5–13 (1987).
   PubMedGoogle Scholar
• Onofrj M, Ghilardi MF, Faricelli A, Bodis-Wollner I, Calvani M. Effect of levo-acetylcarnitine on P300-like potentials of the normal monkey. Drugs Exp. Clin. Res. 13(7), 407–415 (1987).
   PubMedGoogle Scholar
• Siliprandi N, Siliprandi D, Ciman M. Stimulation of oxidation of mitochondrial fatty acids and of acetate by acetylcarnitine. Biochem. J. 96(3), 777–780 (1965).
   PubMedGoogle Scholar
• Amenta F, Ferrante F, Lucreziotti R, Ricci A, Ramacci MT. Reduced lipofuscin accumulation in senescent rat brain by long-term Acetyl-L-carnitine treatment. Arch. Gerontol. Geriatr. 9(2), 147–153 (1989).
   PubMedGoogle Scholar
• Ramacci MT, De Rossi M, Lucreziotti MR, Mione MC, Amenta F. Effect of long-term treatment with Acetyl-L-carnitine on structural changes of ageing rat brain. Drugs Exp. Clin. Res. 14(9), 593–601 (1988).
   PubMedGoogle Scholar
• Fernandez E, Pallini R, Gangitano C et al. Effects of l-carnitine, l-acetylcarnitine and gangliosides on the regeneration of the transected sciatic nerve in rats. Neurol. Res. 11(1), 57–62 (1989).
   PubMedGoogle Scholar
• Pettorossi VE, Brunetti O, Carobi C, Della Torre G, Grassi S. l-acetylcarnitine enhances functional muscle re-innervation. Drugs Exp. Clin. Res. 17(2), 119–125 (1991).
   PubMedGoogle Scholar
• De Angelis C, Scarfò C, Falcinelli M, Reda E, Ramacci MT, Angelucci L. Levocarnitine acetyl stimulates peripheral nerve regeneration and neuromuscular junction remodelling following sciatic nerve injury. Int. J. Clin. Pharmacol. Res. 12(5–6), 269–279 (1992).
   PubMedGoogle Scholar
• De Simone R, Aloe L, Ferraris L, Ramacci MT. Levocarnitine acetyl treatment promotes iris reinnervation following 6-hydroxydopamine-induced noradrenergic denervation in rats. Int. J. Clin. Pharmacol. Res. 12(5–6), 281–287 (1992).
   PubMedGoogle Scholar
• Tenconi B, Donadoni L, Germani E et al. Intraspinal degenerative atrophy caused by sciatic nerve lesions prevented by Acetyl-L-carnitine. Int. J. Clin. Pharmacol. Res. 12(5–6), 263–267 (1992).
   PubMedGoogle Scholar
• Mezzina C, De Grandis D, Calvani M, Marchionni A, Pomes A. Idiopathic facial paralysis: new therapeutic prospects with Acetyl-L-carnitine. Int. J. Clin. Pharmacol. Res. 12(5–6), 299–304 (1992).
   PubMedGoogle Scholar
• Pettorossi VE, Draicchio F, Fernandez E, Pallini R. The influence of l-acetylcarnitine on reinnervation of the oculomotor nerve. Int. J. Clin. Pharmacol. Res. 13(3), 193–199 (1993).
   PubMedGoogle Scholar
• De Angelis C, Scarfò C, Falcinelli M et al. Acetyl-L-carnitine prevents age-dependent structural alterations in rat peripheral nerves and promotes regeneration following sciatic nerve injury in young and senescent rats. Exp. Neurol. 128(1), 103–114 (1994).
   PubMed Web of Science ®Google Scholar
• Hart AM, Wiberg M, Youle M, Terenghi G. Systemic Acetyl-L-carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma. Exp. Brain Res. 145(2), 182–189 (2002).
   PubMed Web of Science ®Google Scholar
• McKay-Hart A, Wiberg M, Terenghi G. Pharmacological enhancement of peripheral nerve regeneration in the rat by systemic Acetyl-L-carnitine treatment. Neurosci. Lett. 334(3), 181–185 (2002).
   PubMedGoogle Scholar
• Wilson AD, Hart A, Brannstrom T, Wiberg M, Terenghi G. Primary sensory neuronal rescue with systemic Acetyl-L-carnitine following peripheral axotomy. A dose-response analysis. Br. J. Plast. Surg. 56(8), 732–739 (2003).
   PubMedGoogle Scholar
• Wilson AD, Hart A, Brännström T, Wiberg M, Terenghi G. Delayed Acetyl-L-carnitine administration and its effect on sensory neuronal rescue after peripheral nerve injury. J. Plast. Reconstr. Aesthet. Surg. 60(2), 114–118 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson AD, Hart A, Wiberg M, Terenghi G. Acetyl-L-carnitine increases nerve regeneration and target organ reinnervation - a morphological study. J. Plast. Reconstr. Aesthet. Surg. 63(7), 1186–1195 (2010).
   PubMed Web of Science ®Google Scholar
• Di Giulio AM, Gorio A, Bertelli A, Mantegazza P, Ferraris L, Ramacci MT. Acetyl-L-carnitine prevents substance P loss in the sciatic nerve and lumbar spinal cord of diabetic animals. Int. J. Clin. Pharmacol. Res. 12(5–6), 243–246 (1992).
   PubMedGoogle Scholar
• Ido Y, McHowat J, Chang KC et al. Neural dysfunction and metabolic imbalances in diabetic rats: prevention by Acetyl-L-carnitine. Diabetes 43, 1469–1477 (1994).
   PubMedGoogle Scholar
• Sima AA, Ristic H, Merry A et al. The primary preventive and secondary interventionary effects of Acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J. Clin. Invest. 97, 1900–1907 (1996).
   PubMed Web of Science ®Google Scholar
• Stevens MJ, Lattimer SA, Feldman EL et al. Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na_/K_-ATPase activity and motor conduction velocity in the streptozotocin diabetic rat. Metabolism 45, 865–872 (1996).
   PubMed Web of Science ®Google Scholar
• Scarpini E, Doneda P, Pizzul S et al. L-carnitine and Acetyl-L-carnitine in human nerves from normal and diabetic subjects. J. Peripher. Nerv. Syst. 1(2), 157–163 (1996).
   PubMedGoogle Scholar
• Ebeling P, Tuominen JA, Arenas J, Garcia Benayas C, Koivisto VA. The association of Acetyl-L-carnitine with glucose and lipid metabolism in human muscle in vivo: the effect of hyperinsulinemia. Metabolism 46(12), 1454–1457 (1997).
   PubMedGoogle Scholar
• Giancaterini A, De Gaetano A, Mingrone G et al. Acetyl-L-carnitine infusion increases glucose disposal in type 2 diabetic patients. Metabolism 49(6), 704–708 (2000).
   PubMed Web of Science ®Google Scholar
• Evans JD, Jacobs TF, Evans EW. Role of Acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann. Pharmacother. 42(11), 1686–1691 (2008).
   PubMed Web of Science ®Google Scholar
• Gadaleta MN, Petruzzella V, Daddabbo L et al. Mitochondrial DNA transcription and translation in aged rat. Effect of Acetyl-L-carnitine. Ann. N Y Acad. Sci. 717, 150–160 (1994).
   PubMed Web of Science ®Google Scholar
• Gadaleta MN, Cormio A, Pesce V, Lezza AM, Cantatore P. Aging and mitochondria. Biochimie 80(10), 863–870 (1998).
   PubMed Web of Science ®Google Scholar
• Pisano C, Pratesi G, Laccabue D et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of Acetyl-L-carnitine. Clin. Cancer Res. 9(15), 5756–5767 (2003).
   PubMed Web of Science ®Google Scholar
• Bianchi G, Vitali G, Caraceni A et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral Acetyl-L-carnitine. Eur. J. Cancer 41(12), 1746–1750 (2005).
   PubMed Web of Science ®Google Scholar
• Ghirardi O, Lo Giudice P, Pisano C et al. Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res. 25(4), 2681 (2005).
   PubMed Web of Science ®Google Scholar
• Ghirardi O, Vertechy M, Vesci L et al. Chemotherapy-induced allodynia: neuroprotective effect of Acetyl-L-carnitine. In Vivo 19(3), 631–637 (2005).
   PubMedGoogle Scholar
• Flatters SJ, Xiao WH, Bennett GJ. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci. Lett. 397(3), 219–223 (2006).
   PubMed Web of Science ®Google Scholar
• Vanotti A, Osio M, Mailland E, Nascimbene C, Capiluppi E, Mariani C. Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. CNS Drugs 21(1), 3–12; (2007).
   PubMedGoogle Scholar
• Mancinelli A, D’Iddio S, Bisonni R, Graziano F, Lippe P, Calvani M. Urinary excretion of l-carnitine and its short-chain Acetyl-L-carnitine in patients undergoing carboplatin treatment. Cancer Chemother. Pharmacol. 60(1), 19–26 (2007).
   PubMed Web of Science ®Google Scholar
• Xiao WH, Bennett GJ. Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by Acetyl-L-carnitine. Pain 135(3), 262 (2008).
   PubMed Web of Science ®Google Scholar
• Virmani MA, Biselli R, Spadoni A et al. Protective actions of l-carnitine and Acetyl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol. Res. 32(6), 383–389 (1995).
   PubMed Web of Science ®Google Scholar
• Famularo G, Moretti S, Marcellini S et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 11(2), 185–190 (1997).
   PubMed Web of Science ®Google Scholar
• Famularo G, De Simone C. Treatment with Acetyl-L-carnitine has the potential to improve the clinical course of painful peripheral neuropathies in HIV-positive patients. J. Peripher. Nerv. Syst. 3(3), 227–229 (1998).
   PubMed Web of Science ®Google Scholar
• Youle M. Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy. CNS Drugs 21(1), 25–30 (2007).
   PubMedGoogle Scholar
• Herzmann C, Johnson MA, Youle M. Long-term effect of Acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clin. Trials 6(6), 344–350 (2005).
   PubMed Web of Science ®Google Scholar
• Osio M, Muscia F, Zampini L et al. Acetyl-L-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J. Peripher. Nerv. Syst. 11(1), 72–76 (2006).
   PubMedGoogle Scholar
• Ferraresi R, Troiano L, Roat E et al. Protective effect of Acetyl-L-carnitine against oxidative stress induced by antiretroviral drugs. FEBS Lett. 580(28–29), 6612–6616 (2006).
   PubMedGoogle Scholar
• Valcour V, Yeh TM, Bartt R et al. AIDS Clinical Trials Group (ACTG) 5157 protocol team. Acetyl-L-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIV Med. 10(2), 103–110 (2009).
   PubMed Web of Science ®Google Scholar
• De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D. 3, 223–231 (200).
   PubMedGoogle Scholar
• Youle M, Osio M; ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl l-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med. 8(4), 241–250 (2007).
   PubMed Web of Science ®Google Scholar
• Ghelardini C, Galeotti N, Calvani M, Mosconi L, Nicolai R, Bartolini A. Acetyl-L-carnitine induces muscarinic antinociception in mice and rats. Neuropharmacology 43(7), 1180–1187 (2002).
   PubMedGoogle Scholar
• Di Cesare Mannelli L, Ghelardini C, Calvani M et al. Neuroprotective effects of Acetyl-L-carnitine on neuropathic pain and apoptosis: a role for the nicotinic receptor. J. Neurosci. Res. 87, 200–207 (2009).
   PubMedGoogle Scholar
• Vivoli E, Di Cesare Mannelli L, Salvicchi A et al. Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy. Neuroscience 167(4), 1168–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Malaguarnera M. Carnitine derivatives: clinical usefulness. Curr. Opin. Gastroenterol. 28(2), 166–176 (2012).
   PubMed Web of Science ®Google Scholar
• Zhou P, Chen Z, Zhao N et al. Acetyl-L-carnitine attenuates homocysteine-induced Alzheimer-like histopathological and behavioral abnormalities. Rejuvenation Res. 14(6), 669–679 (2011).
   PubMedGoogle Scholar
• Jiang X, Tian Q, Wang Y et al. Acetyl-L-carnitine ameliorates spatial memory deficits induced by inhibition of phosphoinositol-3 kinase and protein kinase C. J. Neurochem. 118(5), 864–878 (2011).
   PubMedGoogle Scholar
• Ruggenenti P, Cattaneo D, Loriga G et al. Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of Acetyl-L-carnitine therapy. Hypertension 54(3), 567–574 (2009).
   PubMed Web of Science ®Google Scholar
• McLeod JG. Investigation of peripheral neuropathy. J. Neurol. Neurosurg. Psichiatry. 58, 274–283 (1995).
   PubMed Web of Science ®Google Scholar
• Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern. Med. Rev. 11(4), 294–329 (2006).
   PubMed Web of Science ®Google Scholar
• Bosch EP, Pelhan RW, Rasool CB. Animal models of alcoholic neuropathy: morphologic, electrophysiologic and biochemical findings. Muscle Nerve 2, 133–144 (1979).
   PubMedGoogle Scholar
• Di Cesare Mannelli L, Ghelardini C, Calvani M et al. Protective effect of Acetyl-L-carnitine on the apoptotic pathway of peripheral neuropathy. Eur. J. Neurosc. 26, 820–827 (2007).
   PubMed Web of Science ®Google Scholar
• Mansour HH. Protective role of carnitine ester against radiation-induced oxidative stress in rats. Pharmacol. Res. 54, 165–171 (2006).
   PubMed Web of Science ®Google Scholar
• Merskey H. Clarifying definition of neuropathic pain. Pain 96, 408–409 (2002).
   PubMed Web of Science ®Google Scholar
• Ossipov MH. Growth factors and neuropathic pain. Curr. Pain Headache Rep. 15, 185–192 (2011).
   PubMedGoogle Scholar
• Boucher TJ, McMahon SB. Neurotrophic factors and neuropathic pain. Curr. Opin. Pharmacol. 1, 66–72 (2001).
   PubMedGoogle Scholar
• Waxman SG. The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. Pain 6, 133–140 (1999).
   Google Scholar
• Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 9, 1765–1769 (2000).
   Google Scholar
• Ramer MS, French GD, Bisby MA. Wallerian degeneration is required for both neuropathic pain and sympathetic sprouting into the DRG. Pain 72, 71–78 (1997).
   PubMed Web of Science ®Google Scholar
• Sah D, Ossipov M, Porreca F. Neurotrophic factors as novel therapeutics for neuropathic pain. Nat. Rev. Drug Discov. 2, 460–472 (2003).
   PubMed Web of Science ®Google Scholar
• Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu. Rev. Neurosci. 29, 507–538 (2006).
   PubMed Web of Science ®Google Scholar
• Levin GR, Rueff A, Mendell LM. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur. J. Neurosci. 6, 1903–1912 (1994).
   PubMedGoogle Scholar
• Piovesan P, Pacifici L, Taglialatela G, Ramacci MT, Angelucci L. Acetyl-L-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection. Brain Res. 633, 77–82 (1994).
   PubMedGoogle Scholar
• Foreman PJ, Perez-Polo JR, Angelucci L, Ramacci MT, Taglialatela G. Effect of Acetyl-L-carnitine treatment and stress exposure on the nerve growth factor receptor (p75NGFR) mRNA level in the central nervous system of aged rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 19, 117–133 (1995).
   PubMed Web of Science ®Google Scholar
• Galeotti N, Bartolini A, Calvani M, Nicolai R, Ghelardini C. Acetyl-L-carnitine requires phospholipase C-IP3 pathway activation to induce antinociception. Neuropharmacology 472, 286–294 (2004).
   Google Scholar
• Kulkantrakorn K, Lorsuwansiri C, Meesawatsom P. 0.025% Capsaicin Gel for the treatment of painful diabetic neuropathy: a randomized, double-blind, crossover, placebo-controlled trial. Pain Pract. (2012). doi: 10.1111/papr.12013.
   Google Scholar
• Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane. Database Syst. Rev. 21, 1 (2009).
   Google Scholar
• Mehndiratta MM, Hughes RA. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 12, 9 (2012).
   Google Scholar
• Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 15, 8 (2012).
   Google Scholar
• Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat. Rev. Neurol. 7(9), 507–517 (2011).
   PubMed Web of Science ®Google Scholar
• Magy L, Mathis S, Vallat JM. Diagnostic and therapeutic challenges in chronic inflammatory demyelinating polyneuropathy and other immune-mediated neuropathies. Curr. Opin. Crit. Care 17(2), 101–105 (2011).
   PubMedGoogle Scholar